Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.

Clinical pharmacology and therapeutics - 1 May 2015

Wen C C, Yee S W, Liang X, Hoffmann T J, Kvale M N, Banda Y, Jorgenson E, Schaefer C, Risch N, Giacomini K M

Abstract excerpt

The first-line treatment of hyperuricemia, which causes gout, is allopurinol. The allopurinol response is highly variable, with many users failing to achieve target serum uric acid (SUA) levels. No genome-wide association study (GWAS) has examined the genetic factors affecting allopurinol effectiveness. Using 2,027 subjects in Kaiser Permanente's Genetic Epidemiology Research on Adult Health and Aging (GERA)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP-Binding Cassette Transporters

Share to California

Share to Gout Suppressants

Share to Hyperuricemia

Share to Mitoxantrone

Share to Uric Acid

Source

Open in PubMed Open full text

Identifiers

PMID: 25676789
DOI: 10.1002/cpt.89
PMCID: PMC4479153

Genes

ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.PMID 25676789Read ↗

Genome‐Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for AllopurinolSemantic proximity Read ↗

Association between ABCG2 polymorphisms and allopurinol response in gout patients: a systematic review and meta-analysis.Semantic proximity Read ↗

ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approachesSemantic proximity Read ↗

A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level.Semantic proximity Read ↗

ABCG2 as a therapeutic target candidate for gout.Semantic proximity Read ↗

Metabolic Interactions of Purine Derivatives with Human ABC Transporter ABCG2: Genetic Testing to Assess Gout RiskSemantic proximity Read ↗

The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update.Semantic proximity Read ↗

Association of rare and common genetic variants in MOCOS with inadequate response to allopurinol.Semantic proximity Read ↗

ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.Semantic proximity Read ↗

Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis.Semantic proximity Read ↗

The genetics of gout: towards personalised medicine?Semantic proximity Read ↗

Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.